These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29237959)

  • 61. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
    Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
    Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):102-6. PubMed ID: 18683793
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma.
    Castelli R; Pantaleo G; Gallipoli P; Gidaro A; Arquati M; Wu MA; Lambertenghi Deliliers G
    Anticancer Drugs; 2015 Nov; 26(10):1078-82. PubMed ID: 26295869
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients.
    de Waal EG; de Munck L; Hoogendoorn M; Woolthuis G; van der Velden A; Tromp Y; Vellenga E; Hovenga S
    Br J Haematol; 2015 Dec; 171(5):720-5. PubMed ID: 26358087
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
    Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
    Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
    Sood R; Carloss H; Kerr R; Lopez J; Lee M; Druck M; Walters IB; Noga SJ
    Am J Hematol; 2009 Oct; 84(10):657-60. PubMed ID: 19731393
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management.
    Wu P; Oren O; Gertz MA; Yang EH
    Curr Oncol Rep; 2020 Jun; 22(7):66. PubMed ID: 32514632
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity.
    Gendreau S; Berzero G; Tafani C; Raynouard I; Ricard D; Malfuson JV; Viala K; Debs R; Houillier C; Diamanti L; Marchioni E; Lenglet T; Ouzegdouh M; Bihan K; Gilardin L; Psimaras D
    Acta Oncol; 2020 Apr; 59(4):484-489. PubMed ID: 32122210
    [No Abstract]   [Full Text] [Related]  

  • 71. Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma.
    Chan KL; Filshie R; Nandurkar H; Quach H
    Leuk Lymphoma; 2015 Jul; 56(7):2185-6. PubMed ID: 25547654
    [No Abstract]   [Full Text] [Related]  

  • 72. Atypical bortezomib-induced neutrophilic dermatosis.
    Lescoat A; Dupuy A; Belhomme N; Stock N; Sebillot M; Decaux O; Jégo P; Droitcourt C
    Ann Hematol; 2019 May; 98(5):1315-1316. PubMed ID: 30315343
    [No Abstract]   [Full Text] [Related]  

  • 73. Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy.
    Meseeha MG; Kolade VO; Attia MN
    J Community Hosp Intern Med Perspect; 2015; 5(6):28982. PubMed ID: 26653686
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Arginase Inhibition Mitigates Bortezomib-Exacerbated Cardiotoxicity in Multiple Myeloma.
    Paterek A; Oknińska M; Pilch Z; Sosnowska A; Ramji K; Mackiewicz U; Golab J; Nowis D; Mączewski M
    Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046852
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity.
    Diwadkar S; Patel AA; Fradley MG
    Case Rep Cardiol; 2016; 2016():3456287. PubMed ID: 26942019
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cardiotoxicity due to chemotherapy for breast cancer: the dark side of the moon.
    Peruzzi M; Palazzoni G; Biondi-Zoccai G; Lotrionte M
    Anatol J Cardiol; 2015 Jan; 15(1):61-2. PubMed ID: 25550249
    [No Abstract]   [Full Text] [Related]  

  • 77. Bortezomib Plus Melphalan-Induced Cardiomyopathy Presenting as Sinus Tachycardia and Systolic Heart Failure.
    Sampat PJ; Riaz S; Martinez F; Aiello D
    Cureus; 2020 Jul; 12(7):e9488. PubMed ID: 32775113
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Serial Mapping for Evaluating Cardiac Therapies: Promising, But Not Perfect.
    Sanz J; García-Ruiz JM
    JACC Cardiovasc Imaging; 2020 Apr; 13(4):963-965. PubMed ID: 32273083
    [No Abstract]   [Full Text] [Related]  

  • 79. Radiation therapy-related cardiotoxicity: Every detail counts?
    Timóteo AT
    Int J Cardiol; 2022 Mar; 350():94-95. PubMed ID: 34998945
    [No Abstract]   [Full Text] [Related]  

  • 80. In Regard to Cahlon et al.
    Chang JS; Kim YB; Shin J
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1298-1299. PubMed ID: 29722673
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.